<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SIGNIFOR- pasireotide injection </strong><br>Novartis Pharmaceuticals Corporation<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">These highlights do not include all the information needed to use SIGNIFOR safely and effectively. See full prescribing information for SIGNIFOR.</span><br><br><span class="Bold">SIGNIFOR (pasireotide) injection, for subcutaneous use</span><br><span class="Bold">Initial U.S. Approval: 2012</span><br>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">SIGNIFOR is a somatostatin analog indicated for the treatment of adult patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative (<a href="#_1_INDICATIONS_AND">1</a>) </p></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>Recommended initial dosage is either 0.6 mg or 0.9 mg by subcutaneous injection twice a day; recommended dosage range is 0.3 mg to 0.9 mg twice a day (<a href="#_2_1_Recommended_Dosage">2.1</a>) <br>
</li>
<li>Titrate dosage based on treatment response [clinically meaningful reduction in 24-hour urinary free cortisol (UFC) and/or improvements in signs and symptoms of disease] and tolerability (<a href="#_2_1_Recommended_Dosage">2.1</a>) <br>
</li>
<li>
<span class="Underline">Testing Prior to Dosing</span>: fasting plasma glucose, hemoglobin A1c, liver tests, electrocardiogram (ECG), gallbladder ultrasound, and serum potassium and magnesium levels (<a href="#_2_2_Recommendations_Prior">2.2</a>)<br>
</li>
<li>
<span class="Underline">Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span>: 
									<ul>
<li>
<span class="Italics">Child-Pugh B:</span> Recommended initial dosage is 0.3 mg twice a day and maximum dosage is 0.6 mg twice a day (<a href="#_2_3_Dosage_in">2.3</a>, <a href="#_8_6_Hepatic_Impairment">8.6</a>)</li>
<li>
<span class="Italics">Child-Pugh C:</span> Avoid use in these patients (<a href="#_2_3_Dosage_in">2.3</a>, <a href="#_8_6_Hepatic_Impairment">8.6</a>)</li>
</ul>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Injection: 0.3 mg/mL, 0.6 mg/mL, and 0.9 mg/mL in a single-dose ampule (<a href="#_3_DOSAGE_FORMS">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None (<a href="#_4_CONTRAINDICATIONS">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>
<span class="Italics">Hypocortisolism:</span> Decreases in circulating levels of cortisol may occur resulting in biochemical and/or clinical hypocortisolism. SIGNIFOR dose reduction or interruption and/or adding a low-dose short-term glucocorticoid may be necessary (<a href="#_5_1_Hypocortisolism">5.1</a>)<br>
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span></span> (occurs with initiation): Intensive glucose monitoring is recommended and may require initiation or adjustment of anti-diabetic treatment per standard of care (<a href="#_5_2_Hyperglycemia_and">5.2</a>)<br>
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> and QT Prolongation:</span> Use with caution in at-risk patients; ECG testing prior to dosing and on treatment (<a href="#_5_3_Bradycardia_and">5.3</a>, <a href="#_7_1_Effects_of">7.1</a>)<br>
</li>
<li>
<span class="Italics">Liver Test Elevations:</span> Evaluate liver tests prior to and during treatment (<a href="#_5_4_Liver_Test">5.4</a>)<br>
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">Cholelithiasis</span>:</span> Perform gallbladder ultrasounds before starting treatment and at 6-month intervals (<a href="#_5_5_Cholelithiasis">5.5</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions occurring in ≥ 20% of patients are <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">cholelithiasis</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus (<a href="#_6_ADVERSE_REACTIONS">6</a>) </p>
<p class="Highlighta"><span class="Bold"><br><br>To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>
<span class="Italics">Drugs that Prolong QT:</span> Use with caution in patients who are at significant risk of developing QTc prolongation (<a href="#_5_3_Bradycardia_and">5.3</a>, <a href="#_7_1_Effects_of">7.1</a>)<br>
</li>
<li>
<span class="Italics">Cyclosporine:</span> Consider additional monitoring (<a href="#_7_2_Effects_of">7.2</a>)<br>
</li>
<li>
<span class="Italics">Bromocriptine:</span> Consider bromocriptine dose reduction (<a href="#_7_2_Effects_of">7.2</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div>
<p class="Highlighta">Safety and effectiveness of SIGNIFOR in children under 18 years have not been established (<a href="#_8_4_Pediatric_Use">8.4</a>) </p>
<br>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 3/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Bold">1</span>
		     
	<span class="Bold">INDICATIONS AND USAGE</span></a></h1>
<h2><a href="#section-1.1" class="toc">1.1
		     
	Cushing’s Disease</a></h2>
<h1><a href="#section-2" class="toc"><span class="Bold">2</span>
		     
	<span class="Bold">DOSAGE AND ADMINISTRATION</span></a></h1>
<h2><a href="#section-2.1" class="toc">2.1
		     
	Recommended Dosage Range </a></h2>
<h2><a href="#section-2.2" class="toc">2.2
		     
	Recommendations Prior to Initiation of SIGNIFOR</a></h2>
<h2><a href="#section-2.3" class="toc">2.3
		     
	Dosage in Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-2.4" class="toc">2.4
		     
	Important Administration Instructions</a></h2>
<h1><a href="#section-3" class="toc"><span class="Bold">3</span>
		     
	<span class="Bold">DOSAGE FORMS AND STRENGTHS</span></a></h1>
<h1><a href="#section-4" class="toc"><span class="Bold">4</span>
		     
	<span class="Bold">CONTRAINDICATIONS</span></a></h1>
<h1><a href="#section-5" class="toc"><span class="Bold">5</span>
		     
	<span class="Bold">WARNINGS AND PRECAUTIONS</span></a></h1>
<h2><a href="#section-5.1" class="toc">5.1
		     
	Hypocortisolism</a></h2>
<h2><a href="#section-5.2" class="toc">5.2
		     
	<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> and Diabetes </a></h2>
<h2><a href="#section-5.3" class="toc">5.3
		     
	<span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> and QT Prolongation</a></h2>
<h2><a href="#section-5.4" class="toc">5.4
		     
	Liver Test Elevations</a></h2>
<h2><a href="#section-5.5" class="toc">5.5
		     
	Cholelithiasis </a></h2>
<h2><a href="#section-5.6" class="toc">5.6
		     
	Monitoring for Deficiency of Pituitary Hormones</a></h2>
<h1><a href="#section-6" class="toc"><span class="Bold">6</span>
		     
	<span class="Bold">ADVERSE REACTIONS</span></a></h1>
<h2><a href="#section-6.1" class="toc">6.1
		     
	Clinical Trials Experience</a></h2>
<h1><a href="#section-7" class="toc"><span class="Bold">7</span>
		     
	<span class="Bold">DRUG INTERACTIONS</span></a></h1>
<h2><a href="#section-7.1" class="toc">7.1
		     
	Effects of Other Drugs on SIGNIFOR</a></h2>
<h2><a href="#section-7.2" class="toc">7.2
		     
	Effects of SIGNIFOR on Other Drugs</a></h2>
<h1><a href="#section-8" class="toc"><span class="Bold">8</span>
		     
	<span class="Bold">USE IN SPECIFIC POPULATIONS</span></a></h1>
<h2><a href="#section-8.1" class="toc">8.1
		     
	Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2
		     
	Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3
		     
	Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4
		     
	Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5
		     
	Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6
		     
	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.7
		     
	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc"><span class="Bold">10</span>
		     
	<span class="Bold">OVERDOSAGE</span></a></h1>
<h1><a href="#section-10" class="toc"><span class="Bold">11</span>
		     
	<span class="Bold">DESCRIPTION</span></a></h1>
<h1><a href="#section-11" class="toc"><span class="Bold">12</span>
		     
	<span class="Bold">CLINICAL PHARMACOLOGY</span></a></h1>
<h2><a href="#section-11.1" class="toc">12.1
		     
	Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2
		     
	Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3
		     
	Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc"><span class="Bold">13</span>
		     
	<span class="Bold">NONCLINICAL TOXICOLOGY</span></a></h1>
<h2><a href="#section-12.1" class="toc">13.1
		     
	Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc"><span class="Bold">14</span>
		     
	<span class="Bold">CLINICAL STUDIES</span></a></h1>
<h1><a href="#section-14" class="toc"><span class="Bold">16</span>
		     
	<span class="Bold">HOW SUPPLIED/STORAGE AND HANDLING</span></a></h1>
<h2><a href="#section-14.1" class="toc">16.1
		     
	How Supplied</a></h2>
<h2><a href="#section-14.2" class="toc">16.2
		     
	Storage and Handling</a></h2>
<h1><a href="#section-15" class="toc"><span class="Bold">17</span>
		     
	<span class="Bold">PATIENT COUNSELING INFORMATION</span></a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="_1_INDICATIONS_AND"></a><a name="section-1"></a><p></p>
<h1>
<span class="Bold">1</span>
		     
	<span class="Bold">INDICATIONS AND USAGE</span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1"></a><p></p>
<h2>1.1
		     
	Cushing’s Disease</h2>
<p class="First">SIGNIFOR is indicated for the treatment of adult patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-2"></a><p></p>
<h1>
<span class="Bold">2</span>
		     
	<span class="Bold">DOSAGE AND ADMINISTRATION</span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="_2_1_Recommended_Dosage"></a><a name="section-2.1"></a><p></p>
<h2>2.1
		     
	Recommended Dosage Range </h2>
<p class="First">The recommended dosage range of SIGNIFOR is 0.3 to 0.9 mg by subcutaneous injection twice a day. The recommended initial dose is either 0.6 mg or 0.9 mg twice a day. Titrate dose based on response and tolerability. </p>
<p>Patients should be evaluated for a treatment response [clinically meaningful reduction in 24-hour urinary free cortisol (UFC) levels and/or improvement in signs or symptoms of the disease] and should continue receiving therapy with SIGNIFOR as long as benefit is derived <span class="Italics">[see Clinical Studies</span> <span class="Italics">(14)]</span>. Maximum urinary free cortisol reduction is typically seen by two months of treatment <span class="Italics">[see Clinical Studies (14)]</span>. For patients who are started on 0.6 mg twice a day, a dosage increase to 0.9 mg twice a day may be considered based on the response to the treatment, as long as the 0.6 mg dosage is well tolerated by the patient.</p>
<p>Management of suspected adverse reactions may require temporary dose reduction of SIGNIFOR. Dose reduction by 0.3 mg decrements per injection is suggested. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_2_2_Recommendations_Prior"></a><a name="section-2.2"></a><p></p>
<h2>2.2
		     
	Recommendations Prior to Initiation of SIGNIFOR</h2>
<p class="First">Prior to the start of SIGNIFOR, patients should have baseline levels of the following:</p>
<ul class="Disc">
<li>fasting plasma glucose <span class="Italics">[see Warnings and Precautions (5.2)]</span><br>
</li>
<li>hemoglobin A1c <span class="Italics">[see Warnings and Precautions (5.2)]</span><br>
</li>
<li>liver tests <span class="Italics">[see Warnings and Precautions (5.4)]</span>
</li>
<li>serum potassium and magnesium levels <span class="Italics">[see Warnings and Precautions (5.3)]</span>
</li>
</ul>
<p>Patients should also have a baseline electrocardiogram and gallbladder ultrasound <span class="Italics">[see Warnings and Precautions (5.3, 5.5)]</span><span class="Italics">.</span></p>
<p>Treatment of patients with poorly controlled <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus should be intensively optimized with anti-diabetic therapy prior to starting SIGNIFOR <span class="Italics">[see Warnings and Precautions (5.2)]</span><span class="Italics">.</span> </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_2_3_Dosage_in"></a><a name="section-2.3"></a><p></p>
<h2>2.3
		     
	Dosage in Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">For patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh B), the recommended initial dosage is 0.3 mg twice a day and the maximum dosage is 0.6 mg twice a day. Avoid the use of SIGNIFOR in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh C) <span class="Italics">[see Use in Specific Populations (8.6)]</span>.
								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.4"></a><p></p>
<h2>2.4
		     
	Important Administration Instructions</h2>
<p class="First">Instruct patients to:</p>
<ul class="Disc">
<li>Refer to the FDA-approved patient labeling (Instructions for Use) for detailed administration instructions.<br>
</li>
<li>Prior to injection, visually inspect the product for particulate matter and discoloration. Do not use if particulates and/or discoloration are observed.<br>
</li>
<li>Avoid injection in sites showing signs of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> or irritation.<br>
</li>
<li>Prior to injection, gently pinch the skin at the injection site and hold the needle/syringe at an angle of approximately 45 degrees. <br>
</li>
<li>Administer SIGNIFOR subcutaneously by self-injection into the top of the thigh or the abdomen.<br>
</li>
<li>Avoid multiple subcutaneous injections at the same site within short periods of time. Use of the same injection site for two consecutive injections is not recommended. </li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="_3_DOSAGE_FORMS"></a><a name="section-3"></a><p></p>
<h1>
<span class="Bold">3</span>
		     
	<span class="Bold">DOSAGE FORMS AND STRENGTHS</span>
</h1>
<p class="First">Injection: 0.3 mg/mL, 0.6 mg/mL, and 0.9 mg/mL in a single-dose, 1 mL colorless glass ampule.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="_4_CONTRAINDICATIONS"></a><a name="section-4"></a><p></p>
<h1>
<span class="Bold">4</span>
		     
	<span class="Bold">CONTRAINDICATIONS</span>
</h1>
<p class="First">None.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<h1>
<span class="Bold">5</span>
		     
	<span class="Bold">WARNINGS AND PRECAUTIONS</span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="_5_1_Hypocortisolism"></a><a name="section-5.1"></a><p></p>
<h2>5.1
		     
	Hypocortisolism</h2>
<p class="First">Treatment with SIGNIFOR leads to suppression of adrenocorticotropic hormone (ACTH) secretion in Cushing’s disease. Suppression of ACTH may lead to a decrease in circulating levels of cortisol and potentially hypocortisolism.</p>
<p>Monitor and instruct patients on the signs and symptoms associated with hypocortisolism (e.g., <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> or <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>). If hypocortisolism occurs, consider temporary dose reduction or interruption of treatment with SIGNIFOR, as well as temporary, exogenous glucocorticoid replacement therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_5_2_Hyperglycemia_and"></a><a name="section-5.2"></a><p></p>
<h2>5.2
		     
	<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> and Diabetes </h2>
<p class="First">Elevations in blood glucose levels have been seen in healthy volunteers and patients treated with SIGNIFOR. In the Phase III trial, the development of pre-<span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> was observed <span class="Italics">[see Clinical Studies (14)]</span>. In this trial, nearly all patients—including those with normal glucose status at baseline, pre-<span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, and diabetes—developed worsening glycemia in the first two weeks of treatment. Cushing’s disease patients with poor glycemic control (as defined by HbA1c values &gt;8% while receiving anti-diabetic therapy) may be at a higher risk of developing severe <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> and associated complications, e.g., <span class="product-label-link" type="condition" conceptid="4209145" conceptname="Ketoacidosis">ketoacidosis</span>. </p>
<p>Because of this predictable adverse reaction, the glycemic status [fasting plasma glucose (FPG) or hemoglobin A1c (HbA1c)] should be assessed prior to starting treatment with SIGNIFOR. In patients with uncontrolled <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus intensive anti-diabetic therapy should be optimized prior to treatment with SIGNIFOR. Self-monitoring of blood glucose and/or FPG assessments should be done every week for the first two to three months and periodically thereafter, as clinically appropriate, as well as over the first two to four weeks after any dose increase. After treatment discontinuation, glycemic monitoring (e.g., FPG or HbA1c) should be done according to clinical practice. Patients who were initiated on anti-diabetic therapy as a result of SIGNIFOR may require closer monitoring after discontinuation of SIGNIFOR, especially if the anti-diabetic therapy has a risk of causing <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
<p>If <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> develops in a patient treated with SIGNIFOR, the initiation or adjustment of anti-diabetic treatment per standard of care is recommended. The optimal treatment for the management of SIGNIFOR-induced <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> is not known. If uncontrolled <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> persists, despite appropriate medical management, the dose of SIGNIFOR should be reduced or discontinued. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_5_3_Bradycardia_and"></a><a name="section-5.3"></a><p></p>
<h2>5.3
		     
	<span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> and QT Prolongation</h2>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> has been reported with the use of SIGNIFOR <span class="Italics">[see Adverse Reactions (6)]</span>. Patients with cardiac disease and/or risk factors for <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, such as history of clinically significant <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, high-grade <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>, or concomitant use of drugs associated with <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, should be carefully monitored. Dose adjustments of beta-blockers, calcium channel blockers, or correction of electrolyte disturbances may be necessary. </p>
<p><span class="Underline">QT Prolongation</span></p>
<p>SIGNIFOR is associated with QT prolongation. In two thorough QT studies with SIGNIFOR, QT prolongation occurred at therapeutic and supra-therapeutic doses. SIGNIFOR should be used with caution in patients who are at significant risk of developing prolongation of QTc, such as those:</p>
<ul class="Disc">
<li>with congenital <span class="product-label-link" type="condition" conceptid="4008859" conceptname="Prolonged QT interval">long QT</span> prolongation.<br>
</li>
<li>with uncontrolled or significant cardiac disease including recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> or clinically significant <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>.<br>
</li>
<li>on anti-arrhythmic therapy or other substances that are known to lead to QT prolongation.<br>
</li>
<li>with <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> and/or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>.</li>
</ul>
<p>A baseline ECG is recommended prior to initiating therapy with SIGNIFOR and monitoring for an effect on the QTc interval is advisable. <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> and <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> must be corrected prior to SIGNIFOR administration and should be monitored periodically during therapy. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_5_4_Liver_Test"></a><a name="section-5.4"></a><p></p>
<h2>5.4
		     
	Liver Test Elevations</h2>
<p class="First">In the Phase III trial, 5% of patients had an ALT or AST level greater than 3 times the upper limit of normal (ULN). In the entire clinical development program of SIGNIFOR, there were 4 cases of concurrent elevations in ALT (<span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span>) greater than 3 x ULN and bilirubin greater than 2 x ULN: one patient with Cushing’s disease and three healthy volunteers <span class="Italics">[see Adverse Reactions (6</span><span class="Italics">)]</span>. In these cases, total bilirubin elevations were seen either concomitantly or preceding the transaminase elevation.</p>
<p>Monitoring of liver tests should be done after 1 to 2 weeks on treatment, then monthly for 3 months, and every 6 months thereafter. If ALT is normal at baseline and elevations of ALT of 3-5 times the ULN are observed on treatment, repeat the test within a week or within 48 hours if exceeding 5 times ULN. If ALT is abnormal at baseline and elevations of ALT of 3-5 times the baseline values are observed on treatment, repeat the test within a week or sooner if exceeding 5 times ULN. Tests should be done in a laboratory that can provide same-day results. If the values are confirmed or rising, interrupt SIGNIFOR treatment and investigate for probable cause of the findings, which may or may not be SIGNIFOR-related. Serial measures of ALT, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span>, alkaline phosphatase, and total bilirubin, should be done weekly, or more frequently, if any value exceeds 5 times the baseline value in case of abnormal baselines or 5 times the ULN in case of normal baselines. If resolution of abnormalities to normal or near normal occurs, resuming treatment with SIGNIFOR may be done cautiously, with close observation, and only if some other likely cause has been found.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_5_5_Cholelithiasis"></a><a name="section-5.5"></a><p></p>
<h2>5.5
		     
	Cholelithiasis </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">Cholelithiasis</span> has been frequently reported in clinical studies with SIGNIFOR <span class="Italics">[see Adverse Reactions (6)]</span>. Ultrasonic examination of the gallbladder before, and at 6- to 12-month intervals during SIGNIFOR therapy is recommended. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.6"></a><p></p>
<h2>5.6
		     
	Monitoring for Deficiency of Pituitary Hormones</h2>
<p class="First">As the pharmacological activity of SIGNIFOR mimics that of somatostatin, inhibition of pituitary hormones, other than ACTH, may occur. Monitoring of pituitary function (e.g., TSH/free T<span class="Sub">4</span>, GH/IGF-1) should occur prior to initiation of therapy with SIGNIFOR and periodically during treatment should be considered as clinically appropriate. Patients who have undergone transsphenoidal surgery and pituitary irradiation are particularly at increased risk for deficiency of pituitary hormones. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="_6_ADVERSE_REACTIONS"></a><a name="section-6"></a><p></p>
<h1>
<span class="Bold">6</span>
		     
	<span class="Bold">ADVERSE REACTIONS</span>
</h1>
<p class="First">Clinically significant adverse reactions that appear in other sections of the labeling include:</p>
<ul class="Disc">
<li>Hypocortisolism <span class="Italics">[see Warnings and Precautions (5.1)]</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> and Diabetes <span class="Italics">[see Warnings and Precautions (5.2)]</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> and QT prolongation <span class="Italics">[see Warnings and Precautions (5.3)]</span><br>
</li>
<li>Liver Test Elevations <span class="Italics">[see Warnings and Precautions (5.4)]</span><br>
</li>
<li>Cholelithiasis <span class="Italics">[see Warnings and Precautions (5.5)]</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4254542" conceptname="Hypopituitarism">Pituitary Hormone Deficiency</span> <span class="Italics">[see Warnings and Precautions (5.6)]</span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2>6.1
		     
	Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>A total of 162 Cushing’s disease patients were exposed to SIGNIFOR in the Phase III study <span class="Italics">[see Clinical Studies (14)]</span>.  At study entry, patients were randomized to receive twice a day (b.i.d.) doses of either 0.6 mg or 0.9 mg of SIGNIFOR given subcutaneously. The mean age of patients was approximately 40 years old with a predominance of female patients (78%). The majority of the patients had persistent or recurrent Cushing’s disease (83%) and few patients (≤ 5%) in either treatment group had received previous pituitary irradiation. The median exposure to the treatment was 10.4 months (0.03–37.8) with 68% of patients having at least six-months exposure.</p>
<p>In the Phase III trial, adverse reactions were reported in 98% of patients. The most common adverse reactions (frequency ≥ 20% in either group) were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">cholelithiasis</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus. There were no <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> during the study. Serious adverse events were reported in 25% of patients. Adverse events leading to study discontinuation were reported in 17% of patients.</p>
<p>Adverse reactions with an overall frequency higher than 5% are presented in Table 1 by randomized dose group and overall. Adverse reactions are ranked by frequency, with the most frequent reactions listed first.</p>
<table>
<caption><span>Table 1 - Adverse reactions [n (%)] with an overall frequency of more than 5% in the combined dose group in the Phase III study in Cushing’s disease patients</span></caption>
<col width="200">
<col width="147">
<col width="150">
<col width="111">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center" valign="bottom"></td>
<td class="Toprule" align="center" valign="top">SIGNIFOR<br>0.6 mg bid<br>N=82</td>
<td class="Toprule" align="center" valign="top">SIGNIFOR<br>0.9 mg bid<br>N=80</td>
<td class="Toprule" align="center" valign="top">Overall<br>N=162</td>
</tr>
<tr>
<td class="Toprule"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Toprule" align="center">48 (59)</td>
<td class="Toprule" align="center">46 (58)</td>
<td class="Toprule" align="center">94 (58)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center">38 (46)</td>
<td align="center">46 (58)</td>
<td align="center">84 (52)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></td>
<td align="center">31 (38)</td>
<td align="center">34 (43)</td>
<td align="center">65 (40)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">Cholelithiasis</span></td>
<td align="center">25 (30)</td>
<td align="center">24 (30)</td>
<td align="center">49 (30)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center">23 (28)</td>
<td align="center">23 (29)</td>
<td align="center">46 (28)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td align="center">19 (23)</td>
<td align="center">20 (25)</td>
<td align="center">39 (24)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="center">12 (15)</td>
<td align="center">19(24)</td>
<td align="center">31 (19)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> mellitus</td>
<td align="center">13 (16)</td>
<td align="center">16 (20)</td>
<td align="center">29 (18)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection site reactions</span></td>
<td align="center">14 (17)</td>
<td align="center">14 (18)</td>
<td align="center">28 (17)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></td>
<td align="center">10 (12)</td>
<td align="center">11 (14)</td>
<td align="center">21 (13)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></td>
<td align="center">10 (12)</td>
<td align="center">10 (13)</td>
<td align="center">20 (12)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td align="center">13 (16)</td>
<td align="center">5 (6)</td>
<td align="center">18 (11)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4123836" conceptname="Glycosylated hemoglobin">Glycosylated hemoglobin</span> increased</td>
<td align="center">10 (12)</td>
<td align="center">8 (10)</td>
<td align="center">18 (11)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">Alanine aminotransferase</span> increased</td>
<td align="center">11 (13)</td>
<td align="center">6 (8)</td>
<td align="center">17 (10)</td>
</tr>
<tr>
<td>Gamma-glutamyl transferase increased</td>
<td align="center">10 (12)</td>
<td align="center">7 (9)</td>
<td align="center">17 (10)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Edema peripheral</span></td>
<td align="center">9 (11)</td>
<td align="center">8 (10)</td>
<td align="center">17 (10)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Abdominal pain upper</span></td>
<td align="center">10 (12)</td>
<td align="center">6 (8)</td>
<td align="center">16 (10)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span></td>
<td align="center">7 (9)</td>
<td align="center">9 (11)</td>
<td align="center">16 (10)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">Hypercholesterolemia</span></td>
<td align="center">7 (9)</td>
<td align="center">9 (11)</td>
<td align="center">16 (10)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td align="center">8 (10)</td>
<td align="center">8 (10)</td>
<td align="center">16 (10)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center">8 (10)</td>
<td align="center">7 (9)</td>
<td align="center">15 (9)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></td>
<td align="center">12 (15)</td>
<td align="center">3 (4)</td>
<td align="center">15 (9)</td>
</tr>
<tr>
<td>Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus</td>
<td align="center">10 (12)</td>
<td align="center">5 (6)</td>
<td align="center">15 (9)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td align="center">5 (6)</td>
<td align="center">9 (11)</td>
<td align="center">14 (9)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span></td>
<td align="center">9 (11)</td>
<td align="center">5 (6)</td>
<td align="center">14 (9)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td align="center">3 (4)</td>
<td align="center">11 (14)</td>
<td align="center">14 (9)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td align="center">10 (12)</td>
<td align="center">4 (5)</td>
<td align="center">14 (9)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td align="center">5 (6)</td>
<td align="center">8 (10)</td>
<td align="center">13 (8)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td align="center">6 (7)</td>
<td align="center">7 (9)</td>
<td align="center">13 (8)</td>
</tr>
<tr>
<td>Lipase increased</td>
<td align="center">7 (9)</td>
<td align="center">5 (6)</td>
<td align="center">12 (7)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td align="center">7 (9)</td>
<td align="center">4 (5)</td>
<td align="center">11 (7)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></td>
<td align="center">5 (6)</td>
<td align="center">6 (8)</td>
<td align="center">11 (7)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center">3 (4)</td>
<td align="center">8 (10)</td>
<td align="center">11 (7)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
<td align="center">4 (5)</td>
<td align="center">6 (8)</td>
<td align="center">10 (6)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">Dry skin</span></td>
<td align="center">5 (6)</td>
<td align="center">5 (6)</td>
<td align="center">10 (6)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4008859" conceptname="Prolonged QT interval">Electrocardiogram QT prolonged</span></td>
<td align="center">5 (6)</td>
<td align="center">5 (6)</td>
<td align="center">10 (6)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></td>
<td align="center">6 (7)</td>
<td align="center">4 (5)</td>
<td align="center">10 (6)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span></td>
<td align="center">6 (7)</td>
<td align="center">4 (5)</td>
<td align="center">10 (6)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">Sinus bradycardia</span></td>
<td align="center">8 (10)</td>
<td align="center">2 (3)</td>
<td align="center">10 (6)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span></td>
<td align="center">4 (5)</td>
<td align="center">6 (8)</td>
<td align="center">10 (6)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">Abdominal distension</span></td>
<td align="center">4 (5)</td>
<td align="center">5 (6)</td>
<td align="center">9 (6)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">Adrenal insufficiency</span></td>
<td align="center">4 (5)</td>
<td align="center">5 (6)</td>
<td align="center">9 (6)</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">Aspartate aminotransferase</span> increased</td>
<td align="center">6 (7)</td>
<td align="center">3 (4)</td>
<td align="center">9 (6)</td>
</tr>
<tr class="Last">
<td>Blood glucose increased</td>
<td align="center">6 (7)</td>
<td align="center">3 (4)</td>
<td align="center">9 (6)</td>
</tr>
</tbody>
</table>
<p>Other notable adverse reactions which occurred with a frequency less than 5% were: <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (4%); blood amylase increased (2%) and <span class="product-label-link" type="condition" conceptid="4260197" conceptname="Prothrombin time increased">prothrombin time prolonged</span> (2%).</p>
<p><span class="Italics Underline"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>, predominantly <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> were reported frequently in the Phase III trial (see Table 1). These events began to develop primarily during the first month of treatment with SIGNIFOR and required no intervention.</p>
<p><span class="Italics Underline"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> </span></p>
<p><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span>-related terms were reported frequently in the Phase III trial. For all patients, these terms included: <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> (40%), <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus (18%), increased HbA1c (11%), and type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus (9%). In general, increases in fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) were seen soon after initiation of SIGNIFOR and were sustained during the treatment period. In the SIGNIFOR 0.6 mg group, mean fasting plasma glucose (FPG) levels increased from 98.6 mg/dL at baseline to 125.1 mg/dL at Month 6. In the SIGNIFOR 0.9 mg group, mean fasting plasma glucose (FPG) levels increased from 97.0 mg/dL at baseline to 128.0 mg/dL at Month 6. In the SIGNIFOR 0.6 mg group, HbA1c increased from 5.8% at baseline to 7.2% at Month 6. In the SIGNIFOR 0.9 mg group, HbA1c increased from 5.8% at baseline to 7.3% at Month 6 <span class="Italics">[see Warning and Precautions (5.2)]</span>.
								</p>
<p>At one-month follow-up visits following discontinuation of SIGNIFOR, mean FPG and HbA1c levels decreased but remained above baseline values. Long-term follow-up data are not available.</p>
<p><span class="Italics Underline">Elevated Liver Tests</span></p>
<p>In the Phase III trial, there were transient mean elevations in aminotransferase values in patients treated with SIGNIFOR. Mean values returned to baseline levels by Month 4 of treatment. The elevations were not associated with clinical symptoms of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>.</p>
<p>In the clinical development program of SIGNIFOR, there were 4 patients with concurrent elevations in ALT greater than 3 x ULN and bilirubin greater than 2 x ULN: one patient with Cushing’s disease and three healthy volunteers <span class="Italics">[see Warnings and Precautions (5.4)]</span>. In all four cases, the elevations were noted within the first 10 days of treatment. In all of these cases, total bilirubin elevations were seen either concomitantly or preceding the transaminase elevation. The patient with Cushing’s disease developed <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>. All four cases had resolution of the laboratory abnormalities with discontinuation of SIGNIFOR.</p>
<p><span class="Italics Underline">Hypocortisolism</span></p>
<p>Cases of hypocortisolism were reported in the Phase III study in Cushing’s disease patients <span class="Italics">[see Adverse Reactions (6) and Clinical Studies (14)]</span>. The majority of cases were manageable by reducing the dose of SIGNIFOR and/or adding low-dose, short-term glucocorticoid therapy <span class="Italics">[see Warnings and Precautions (5.1)]</span>.
								</p>
<p><span class="Italics Underline"><span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection Site Reactions</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection site reactions</span> were reported in 17% of patients enrolled in the Phase III trial in Cushing’s disease. The events were most frequently reported as local <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>. These events resolved spontaneously and required no intervention.</p>
<p><span class="Bold">Thyroid Function</span></p>
<p><span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span> with the use of SIGNIFOR was reported for seven patients participating in the Phase III study in Cushing’s disease. All seven patients presented with a TSH close to or below the lower limit at study entry which precludes establishing a conclusive relationship between the adverse event and the use of SIGNIFOR.</p>
<p><span class="Italics Underline">Other Abnormal Laboratory Findings</span></p>
<p>Asymptomatic and reversible elevations in lipase and amylase were observed in patients receiving SIGNIFOR in clinical studies. <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> is a potential adverse reaction associated with the use of somatostatin analogs due to the association between <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">cholelithiasis</span> and <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span>.</p>
<p>For hemoglobin levels, mean decreases that remained within normal range were observed. Also, post-baseline elevations in PT and PTT were noted in 33% and 47% of patients, respectively. The PT and PTT elevations were minimal. </p>
<p>These laboratory findings are of unclear clinical significance.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1>
<span class="Bold">7</span>
		     
	<span class="Bold">DRUG INTERACTIONS</span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="_7_1_Effects_of"></a><a name="section-7.1"></a><p></p>
<h2>7.1
		     
	Effects of Other Drugs on SIGNIFOR</h2>
<p class="First"><span class="Bold">Drugs that Prolong QT</span></p>
<p>Co-administration of drugs that prolong the QT interval with SIGNIFOR may have additive effects on the prolongation of the QT interval. Caution is required when co-administering SIGNIFOR with drugs that may prolong the QT interval <span class="Italics">[see Warnings and Precautions (5.3)]</span>.
								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_7_2_Effects_of"></a><a name="section-7.2"></a><p></p>
<h2>7.2
		     
	Effects of SIGNIFOR on Other Drugs</h2>
<p class="First"><span class="Bold">Cyclosporine</span></p>
<p>Concomitant administration of cyclosporine with pasireotide may decrease the relative bioavailability of cyclosporine and, therefore, dose adjustment of cyclosporine to maintain therapeutic levels may be necessary.</p>
<p><span class="Bold">Bromocriptine</span></p>
<p>Co-administration of somatostatin analogues with bromocriptine may increase the blood levels of bromocriptine. Dose reduction of bromocriptine may be necessary. </p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1>
<span class="Bold">8</span>
		     
	<span class="Bold">USE IN SPECIFIC POPULATIONS</span>
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.1"></a><p></p>
<h2>8.1
		     
	Pregnancy</h2>
<p class="First"><span class="Bold">Pregnancy Category </span><span class="Bold">C</span></p>
<p>There are no adequate and well-controlled studies in pregnant women. Reproduction studies have been performed in rats and rabbits which showed evidence of harm to the fetus due to pasireotide at therapeutic exposures. Animal reproduction studies are not always predictive of human response. Pasireotide should be used during pregnancy only if clearly needed.</p>
<p>Dosing in rats before mating and continuing into gestation at exposures less than the human clinical exposure based on body surface area comparisons across species, resulted in adverse fertility effects including: statistically significant increased implantation loss and decreased viable fetuses, corpora lutea, and implantation sites. Abnormal cycles or acyclicity were observed at systemic exposure 5-fold higher than the maximum therapeutic exposure based on surface area, comparisons across species <span class="Italics">[see Nonclinical Toxicology (13.1)]</span>.</p>
<p>In embryofetal development studies in rats given 1, 5, and 10 mg/kg/day subcutaneously throughout organogenesis, maternal toxicity was observed at all doses, including the lowest dose tested which had exposures 4-times higher than that at the maximum therapeutic dose based on AUC comparisons across species. </p>
<p>In embryofetal development studies in rabbits given 0.05, 1, and 5 mg/kg/day subcutaneously through organogenesis, maternal toxicity was observed at 1 mg/kg/day at an exposure 7-times higher than the maximum therapeutic exposure. Treatment related increased incidence of skeletal malformations were observed at 0.05 mg/kg/day, exposures less than the maximum therapeutic exposure based on AUC comparisons across species. </p>
<p>In pre- and post-natal developmental studies in rats given subcutaneous doses of 2, 5, and 10 mg/kg/day during gestation through lactation and weaning, maternal toxicity was observed at all doses including the lowest dose (12-times higher than the maximum therapeutic dose based on surface area comparisons across species). Retardation of physiological growth, attributed to GH inhibition was observed at 2 mg/kg/day during a pre- and post-natal study in rats. After weaning, body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gains</span> in the rat pups (F1 generation) exposed to pasireotide were comparable to controls, showing reversibility of this <span class="product-label-link" type="condition" conceptid="436077" conceptname="Developmental delay">developmental delay</span>.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-8.2"></a><p></p>
<h2>8.2
		     
	Labor and Delivery</h2>
<p class="First">No data in humans are available. Studies in rats have shown no effects on labor and delivery <span class="Italics">[see Nonclinical Toxicology (13.1)]</span>.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.3"></a><p></p>
<h2>8.3
		     
	Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when SIGNIFOR is administered to a nursing woman <span class="Italics">[see Nonclinical Toxicology (13.1)]</span>. Pasireotide was excreted into rat milk at levels 30% of the plasma level. As a risk to the breastfed child cannot be excluded, SIGNIFOR should not be used by the nursing mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="_8_4_Pediatric_Use"></a><a name="section-8.4"></a><p></p>
<h2>8.4
		     
	Pediatric Use</h2>
<p class="First">Safety and effectiveness of SIGNIFOR have not been established in pediatric patients.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.5"></a><p></p>
<h2>8.5
		     
	Geriatric Use</h2>
<p class="First">Clinical studies of SIGNIFOR did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and concomitant disease or other drug therapy [see Clinical Pharmacology (12.3)].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_8_6_Hepatic_Impairment"></a><a name="section-8.6"></a><p></p>
<h2>8.6
		     
	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Dose adjustment is not required in patients with mild impaired hepatic function (Child-Pugh A), but is required for patients with moderately impaired hepatic function (Child-Pugh B) [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3)]. Avoid the use of SIGNIFOR in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh C). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.7"></a><p></p>
<h2>8.7
		     
	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">No dosage adjustment of SIGNIFOR in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> is required [see Clinical Pharmacology (12.3)].</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>
<span class="Bold">10</span>
		     
	<span class="Bold">OVERDOSAGE</span>
</h1>
<p class="First">No cases of overdosage have been reported in patients with Cushing’s disease receiving SIGNIFOR subcutaneously. Doses up to 2.1 mg b.i.d. have been used in healthy volunteers with adverse reactions of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> being observed at a high frequency. </p>
<p>In the event of overdosage, it is recommended that appropriate supportive treatment be initiated, as dictated by the patient’s clinical status, until resolution of the symptoms.</p>
<p>Up-to-date information about the treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> can be obtained from a certified Regional Poison Center. </p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-10"></a><p></p>
<h1>
<span class="Bold">11</span>
		     
	<span class="Bold">DESCRIPTION</span>
</h1>
<p class="First">SIGNIFOR (pasireotide) injection is prepared as a sterile solution of pasireotide diaspartate in a tartaric acid buffer for administration by subcutaneous injection. SIGNIFOR is a somatostatin analog. Pasireotide diaspartate, chemically known as (2-Aminoethyl) carbamic acid (2R,5S,8S,11S,14R,17S,19aS)-11-(4-aminobutyl)-5-benzyl-8-(4-benzyloxybenzyl)-14-(1H-indol-3-ylmethyl)-4,7,10,13,16,19-hexaoxo-17-phenyloctadecahydro-3a,6,9,12,15,18-hexaazacyclopentacyclooctadecen-2-yl ester, di[(S)-2-aminosuccinic acid] salt, is a cyclohexapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin.</p>
<p>The molecular formula of pasireotide diaspartate is C<span class="Sub">58</span>H<span class="Sub">66</span>N<span class="Sub">10</span>O<span class="Sub">9</span> • 2 C<span class="Sub">4</span>H<span class="Sub">7</span>NO<span class="Sub">4</span> and the molecular weight is 1313.41. The structural formula is:</p>
<p><img alt="The structural formula of pasireotide diaspartate." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=442f0d9d-5c7d-4b81-b329-d71be8cf2be2&amp;name=signifor-01.jpg"></p>
<p>SIGNIFOR is supplied as a sterile solution in a single-dose, 1 mL colorless glass ampule containing pasireotide in 0.3 mg/mL, 0.6 mg/mL, or 0.9 mg/mL strengths for subcutaneous injection.</p>
<p>Each glass ampule contains: </p>
<table>
<col width="161">
<col width="96">
<col width="96">
<col width="96">
<tbody class="Headless">
<tr class="First">
<td class="Toprule"></td>
<td class="Toprule">0.3 mg</td>
<td class="Toprule">0.6 mg </td>
<td class="Toprule">0.9 mg </td>
</tr>
<tr>
<td class="Toprule">Pasireotide diaspartate</td>
<td class="Toprule">0.3762<span class="Sup">*</span>
</td>
<td class="Toprule">0.7524<span class="Sup">*</span>
</td>
<td class="Toprule">1.1286<span class="Sup">*</span>
</td>
</tr>
<tr>
<td>Mannitol</td>
<td>49.50</td>
<td>49.50</td>
<td>49.50</td>
</tr>
<tr>
<td>Tartaric acid</td>
<td>1.501</td>
<td>1.501</td>
<td>1.501</td>
</tr>
<tr>
<td>Sodium hydroxide</td>
<td>ad pH 4.2</td>
<td>ad pH 4.2</td>
<td>ad pH 4.2</td>
</tr>
<tr>
<td>Water for injection</td>
<td>ad 1 mL</td>
<td>ad 1 mL</td>
<td>ad 1 mL</td>
</tr>
<tr class="Last"><td class="Toprule" colspan="4">
<span class="Sup">*</span> corresponds to 0.3/0.6/0.9 mg pasireotide base<br>Note: Each ampule contains an overfill of 0.1 mL to allow accurate administration of 1 mL from the ampule.</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-11"></a><p></p>
<h1>
<span class="Bold">12</span>
		     
	<span class="Bold">CLINICAL PHARMACOLOGY</span>
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-11.1"></a><p></p>
<h2>12.1
		     
	Mechanism of Action</h2>
<p class="First">SIGNIFOR is an injectable cyclohexapeptide somatostatin analogue. Pasireotide exerts its pharmacological activity via binding to somatostatin receptors (SSTRs). Five human somatostatin receptor subtypes are known: SSTR 1, 2, 3, 4, and 5. These receptor subtypes are expressed in different tissues under normal physiological conditions. Corticotroph tumor cells from Cushing’s disease patients frequently over-express SSTR5 whereas the other receptor subtypes are often not expressed or are expressed at lower levels. Pasireotide binds and activates the SSTRs resulting in inhibition of ACTH secretion, which leads to decreased cortisol secretion.</p>
<p>The binding affinities of endogenous somatostatin and pasireotide are shown in Table 2. </p>
<table>
<caption><span>Table 2- Binding affinities of somatostatin (SRIF-14) and pasireotide to the five human somatostatin receptor subtypes (SSTR1-5)</span></caption>
<col width="150">
<col width="108">
<col width="96">
<col width="96">
<col width="96">
<col width="102">
<tbody class="Headless">
<tr class="First">
<td class="Toprule"><span class="Bold">Compound</span></td>
<td class="Toprule" align="center"><span class="Bold">SSTR1</span></td>
<td class="Toprule" align="center"><span class="Bold">SSTR2</span></td>
<td class="Toprule" align="center"><span class="Bold">SSTR3</span></td>
<td class="Toprule" align="center"><span class="Bold">SSTR4</span></td>
<td class="Toprule" align="center"><span class="Bold">SSTR5</span></td>
</tr>
<tr>
<td class="Toprule">Somatostatin (SRIF-14)</td>
<td class="Toprule" align="center">0.93±0.12</td>
<td class="Toprule" align="center">0.15±0.02</td>
<td class="Toprule" align="center">0.56±0.17</td>
<td class="Toprule" align="center">1.5±0.4</td>
<td class="Toprule" align="center">0.29±0.04</td>
</tr>
<tr>
<td>Pasireotide</td>
<td align="center">9.3±0.1</td>
<td align="center">1.0±0.1</td>
<td align="center">1.5±0.3</td>
<td align="center">&gt; 100</td>
<td align="center">0.16±0.01</td>
</tr>
<tr class="Last"><td class="Toprule" colspan="6">Results are the mean±SEM of IC<span class="Sub">50</span> values expressed as nmol/l</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="section-11.2"></a><p></p>
<h2>12.2
		     
	Pharmacodynamics</h2>
<p class="First"><span class="Bold">Glucose Metabolism</span></p>
<p>In a randomized, double-blind mechanism study conducted in healthy volunteers, the development of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> with pasireotide at doses of 0.6 mg b.i.d. and 0.9 mg b.i.d. was related to significant decreases in insulin secretion as well as incretin hormones (i.e., glucagon-like peptide-1 [GLP-1] and glucose-dependent insulinotropic polypeptide [GIP]) <span class="Italics">[see Warnings and Precautions (5.2) and Adverse Reactions (6.1)]</span>.</p>
<p><span class="Bold">Cardiac Electrophysiology</span></p>
<p>QTcI interval was evaluated in a randomized, blinded, crossover study in healthy subjects investigating pasireotide doses of 0.6 mg b.i.d. and 1.95 mg b.i.d. The maximum mean (95% upper confidence bound) placebo-subtracted QTcI change from baseline was 12.7 (14.7) ms and 16.6 (18.6) ms, respectively. Both pasireotide doses decreased heart rate, with a maximum mean (95% lower confidence bound) placebo-subtracted change from baseline of -10.9 (-11.9) beats per minute (bpm) observed at 1.5 hours for pasireotide 0.6 mg bid, and -15.2 (-16.5) bpm at 0.5 hours for pasireotide 1.95 mg b.i.d. The supra-therapeutic dose (1.95 mg b.i.d) produced mean steady-state C<span class="Sub">max</span> values 3.3-fold the mean C<span class="Sub">max</span> for the 0.6 mg b.i.d dose in the study.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-11.3"></a><p></p>
<h2>12.3
		     
	Pharmacokinetics</h2>
<p class="First">In healthy volunteers, pasireotide demonstrates approximately linear pharmacokinetics (PK) for a dose range from 0.0025 to 1.5 mg. In Cushing’s disease patients, pasireotide demonstrates linear dose-exposure relationship in a dose range from 0.3 to 1.2 mg.</p>
<p><span class="Bold">Absorption and Distribution</span></p>
<p>In healthy volunteers, pasireotide peak plasma concentration is reached within T<span class="Sub">max</span> 0.25-0.5 hour. C<span class="Sub">max</span> and AUC are dose-proportional following administration of single and multiple doses.</p>
<p>No studies have been conducted to evaluate the absolute bioavailability of pasireotide in humans. Food effect is unlikely to occur since SIGNIFOR is administered via a parenteral route.</p>
<p>In healthy volunteers, pasireotide is widely distributed with large apparent volume of distribution (V<span class="Sub">z</span>/F &gt;100 L). Distribution between blood and plasma is concentration independent and shows that pasireotide is primarily located in the plasma (91%). Plasma protein binding is moderate (88%) and independent of concentration.</p>
<p>Pasireotide has low passive permeability and is likely to be a substrate of P-gp (P-glycoprotein), but the impact of P-gp on ADME (absorption, distribution, metabolism, excretion) of pasireotide is expected to be low. In clinical testing in healthy volunteers, P-gp inhibition (e.g., verapamil) did not affect the rate or extent of pasireotide availability. Pasireotide is not a substrate of efflux transporter BCRP (breast cancer resistance protein), influx transporter OCT1 (organic cation transporter 1), or influx transporters OATP (organic anion-transporting polypeptide) 1B1, 1B3, or 2B1.</p>
<p><span class="Bold">Metabolism and Excretion</span></p>
<p>Pasireotide was shown to be metabolically stable in human liver and kidney microsomes systems. In healthy volunteers, pasireotide in its unchanged form is the predominant form found in plasma, urine, and feces. Somatropin may increase CYP450 enzymes and, therefore, suppression of growth hormone secretion by somatostatin analogs including pasireotide may decrease the metabolic clearance of compounds metabolized by CYP450 enzymes.</p>
<p>Pasireotide is eliminated mainly via hepatic clearance (biliary excretion) with a small contribution of the renal route. In a human ADME study 55.9 ± 6.63% of the radioactivity dose was recovered over the first 10 days post dosing, including 48.3 ± 8.16% of the radioactivity in feces and 7.63 ± 2.03% in urine. </p>
<p>The clearance (CL/F) of pasireotide in healthy volunteers and Cushing’s disease patients is ~7.6 L/h and ~3.8 L/h, respectively.</p>
<p><span class="Bold">Steady-state Pharmacokinetics:</span></p>
<p>Following multiple subcutaneous doses, pasireotide demonstrates linear pharmacokinetics in the dose range of 0.05 to 0.6 mg once a day in healthy volunteers, and 0.3 mg to 1.2 mg twice a day in Cushing’s disease patients. Based on the accumulation ratios of AUC, the calculated effective half-life (t<span class="Sub">1/2,eff</span>) in healthy volunteers was approximately 12 hours (on average between 10 and 13 hours for 0.05, 0.2 and 0.6 mg once a day doses).</p>
<p><span class="Bold">Specific Populations:</span></p>
<p>Population PK analyses of SIGNIFOR indicate that race, body weight, age, and gender do not have a clinically relevant influence on PK parameters.  No dose adjustment is required for demographics. </p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>In a clinical study in subjects with impaired hepatic function (Child-Pugh A, B and C), subjects with moderate and severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh B and C) showed significantly higher exposures than subjects with normal hepatic function. Upon comparison with the control group, AUC<span class="Sub">inf</span> was increased by 12%, 56% and 42% and C<span class="Sub">max</span> increased by 3%, 46% and 33%, respectively, in the mild, moderate and severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> groups [see Use in Specific Populations (8.6) and Dosage and Administration (2.3)].</p>
<p><span class="Bold Italics">Pediatric Patients</span></p>
<p>No studies have been performed in pediatric patients [see Use in Specific Populations (8.4)].</p>
<p><span class="Bold Italics">Geriatric Patients</span></p>
<p>No clinical pharmacology studies have been performed in geriatric patients.</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>Clinical pharmacology studies have not been performed in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. However, renal clearance has a minor contribution to the elimination of pasireotide in humans. Renal function is not expected to significantly impact the circulating levels of pasireotide [see Use in Specific Populations (8.7)].</p>
<p><span class="Bold">Drug Interaction Studies</span></p>
<p>There was no significant drug interaction between pasireotide and metformin, nateglinide or liraglutide.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-12"></a><p></p>
<h1>
<span class="Bold">13</span>
		     
	<span class="Bold">NONCLINICAL TOXICOLOGY</span>
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1"></a><p></p>
<h2>13.1
		     
	Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Italics">Carcinogenesis </span></p>
<p>A life-time carcinogenicity study was conducted in rats and transgenic mice. Rats were given daily subcutaneous doses of pasireotide at 0.01, 0.05, 0.3 mg/kg/day for 104 weeks. There were no drug-related tumors in rats at exposures up to 7-fold higher than the maximum recommended clinical exposure at the 1.8 mg/day dose. Mice were given subcutaneous doses of pasireotide at 0.5, 1.0, 2.5 mg/kg/day for 26 weeks and did not identify any carcinogenic potential.</p>
<p><span class="Italics">Mutagenesis </span></p>
<p>Pasireotide was not genotoxic in a battery of in vitro assays (Ames mutation test in <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span> and <span class="Italics">Escherichia coli</span> and mutation test in human peripheral <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>). Pasireotide was not genotoxic in an in vivo rat bone marrow nucleus test.</p>
<p><span class="Italics">Impairment of Fertility</span></p>
<p>Subcutaneous dosing at 0.1 mg/kg/day before mating and continuing into gestation in rats at exposures less than the human clinical exposure based on body surface area comparisons across species resulted in statistically significant increased implantation loss and decreased viable fetuses, corpora lutea, and implantation sites. Abnormal cycles or acyclicity were observed at 1 mg/kg/day (5-fold higher than the maximum therapeutic exposure based on surface area, comparisons across species).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-13"></a><p></p>
<h1>
<span class="Bold">14</span>
		     
	<span class="Bold">CLINICAL STUDIES</span>
</h1>
<p class="First">A Phase III, multicenter, randomized study was conducted to evaluate the safety and efficacy of two dose levels of SIGNIFOR over a 6-month treatment period in Cushing’s disease patients with persistent or recurrent disease despite pituitary surgery or <span class="Italics">de novo</span> patients for whom surgery was not indicated or who had refused surgery. </p>
<p>Patients with a baseline 24-hour urine free cortisol (UFC) &gt;1.5 x upper limit of normal (ULN) were randomized to receive a SIGNIFOR dosage of either 0.6 mg subcutaneous b.i.d. or 0.9 mg subcutaneous b.i.d. After three months of treatment, patients with a mean 24-hour UFC ≤ 2.0 x ULN and below or equal to their baseline values continued blinded treatment at the randomized dose until Month 6. Patients who did not meet these criteria were unblinded and the dose was increased by 0.3 mg b.i.d. After the initial six months in the study, patients entered an additional 6-month open-label treatment period. The dosage could be reduced by 0.3 mg b.i.d. at any time during the study for intolerability. </p>
<p>A total of 162 patients were enrolled in this study. The majority of patients were female (78%) and had persistent or recurrent Cushing’s disease despite pituitary surgery (83%) with a mean age of 40 years. A few patients (4%) in either treatment group received previous pituitary irradiation. The median value of the baseline 24-hour UFC for all patients was 565 nmol/24 hours (normal range 30 to 145 nmol/24 hours). About two-thirds of all randomized patients completed six months of treatment.</p>
<p>The primary efficacy endpoint was the proportion of patients who achieved normalization of mean 24-hour UFC levels after six months of treatment and did not dose increase during this period. </p>
<p><span class="Bold">24-Hour Urinary Free Cortisol</span><span class="Bold"> Results</span></p>
<p>At Month 6, the percentages of responders for the primary endpoint were 15% and 26% in the 0.6 mg b.i.d. and 0.9 mg b.i.d. groups, respectively (Table 3). The percentages of patients with mUFC ≤ ULN or ≥ 50% reduction from baseline, a less stringent endpoint than the primary endpoint, were 34% in the 0.6 mg bid and 41% in the 0.9 mg bid groups. Dose increases appeared to have minimal effect on 24-hour UFC response. Mean and median percentage changes in UFC from baseline are presented in Table 3.</p>
<table>
<caption><span>Table 3- 24-Hour Urinary Free Cortisol (UFC) Study Results at Month 6 in Patients with Cushing’s Disease</span></caption>
<col width="192">
<col width="210">
<col width="204">
<tbody class="Headless">
<tr class="First">
<td></td>
<td align="center">
<span class="Bold">SIGNIFOR</span><br><span class="Bold">0.6 mg b.i.d.</span><br><span class="Bold">N=82</span>
</td>
<td align="center">
<span class="Bold">SIGNIFOR</span><br><span class="Bold">0.9 mg b.i.d.</span><br><span class="Bold">N=80</span>
</td>
</tr>
<tr>
<td>
<span class="Bold">UFC Responders</span><br><span class="Bold">     n/N</span><br><span class="Bold">     % (95% CI)</span>
</td>
<td align="center">12/82<br>15% (7%, 22%)</td>
<td align="center">21/80<br>26% (17%, 36%)</td>
</tr>
<tr>
<td></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td class="Toprule">
<span class="Bold">UFC Levels </span>(nmol/24hr)<span class="Bold"> </span><br><span class="Bold">  Baseline </span><br><span class="Bold">     Mean (SD)</span><br><span class="Bold">     Median</span>
</td>
<td class="Toprule" align="center">N=78<br><br>868 (764)<br>704</td>
<td class="Toprule" align="center">N=72<br><br>750 (930)<br>470</td>
</tr>
<tr class="Last">
<td class="Toprule">
<span class="Bold">  % Change from baseline</span><br><span class="Bold">     Mean (95% CI) </span><br><span class="Bold">     Median</span>
</td>
<td class="Toprule" align="center">
<br>-22% (-44%, +1%)<br>-47%</td>
<td class="Toprule" align="center">
<br>-42% (-50%, -33%)<br>-46%</td>
</tr>
</tbody>
</table>
<p>SIGNIFOR resulted in a decrease in the mean 24-hour UFC after 1 month of treatment (Figure 1). For patients (n=78) who stayed in the trial, similar UFC lowering was observed at Month 12. </p>
<div class="Figure">
<img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=442f0d9d-5c7d-4b81-b329-d71be8cf2be2&amp;name=signifor-02.jpg"><p class="MultiMediaCaption">Figure 1 - Mean (±SE) Urinary Free Cortisol (nmol/24h) at time points up to Month 6 by randomized dose group</p>
</div>
<p>Note: Only patients who completed 6 months of treatment are included in this analysis (n=110). The reference line is the upper limit of normal for UFC, which is 145 nmol/24hour; +/-Standard errors are displayed.</p>
<p><span class="Bold">O</span><span class="Bold">ther endpoints</span></p>
<p>Decreases from baseline for blood pressure were observed at Month 6, including patients who did not receive any antihypertensive medication. However, due to the fact that the study allowed initiation of antihypertensive medication and dose increases in patients already receiving such medications, the individual contribution of SIGNIFOR or of antihypertensive medication adjustments cannot be clearly established. </p>
<p>The mean decreases from baseline at Month 6 for weight, body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index and waist circumference were 4.4 kg, 1.6 kg/m<span class="Sup">2</span> and 2.6 cm, respectively. Individual patients showed varying degrees of improvement in Cushing's disease manifestations but because of the variability in response and the absence of a control group in this trial, it is uncertain whether these changes could be ascribed to the effects of SIGNIFOR.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<h1>
<span class="Bold">16</span>
		     
	<span class="Bold">HOW SUPPLIED/STORAGE AND HANDLING</span>
</h1>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14.1"></a><p></p>
<h2>16.1
		     
	How Supplied</h2>
<p class="First">SIGNIFOR is supplied as a single dose, colorless glass ampule packaged in a box of 60 ampules, arranged in 10 packs of 6 ampules each. The following packaging configurations are available.</p>
<p><span class="Italics">0.3 mg/1 mL pasireotide (as diaspartate)</span></p>
<p>Box of 60 ampules
		     
	NDC# 0078-0633-20</p>
<p><span class="Italics">0.6 mg/1 mL pasireotide (as diaspartate)</span><span class="Italics"> </span></p>
<p>Box of 60 ampules
		     
	NDC# 0078-0634-20</p>
<p><span class="Italics">0.9 mg/1 mL pasireotide (as diaspartate)</span><span class="Italics"> </span></p>
<p>Box of 60 ampules
		     
	NDC# 0078-0635-20</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.2"></a><p></p>
<h2>16.2
		     
	Storage and Handling</h2>
<p class="First">Store at 25° C (77°F); excursions permitted to 15°–30°C (59°–86°F), protect from light.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-15"></a><p></p>
<h1>
<span class="Bold">17</span>
		     
	<span class="Bold">PATIENT COUNSELING INFORMATION</span>
</h1>
<p class="First">See FDA approved patient labeling (Medication Guide and Instructions for Use).</p>
<p>Counsel patients on the following possible significant adverse reactions:</p>
<ul class="Disc">
<li>Hypocortisolism <span class="Italics">[see Warnings and Precautions (5.1)]</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> <span class="Italics">[see Warnings and Precautions (5.2)]</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> and QT prolongation <span class="Italics">[see Warnings and Precautions (5.3)]</span><br>
</li>
<li>Liver test elevations <span class="Italics">[see Warnings and Precautions (5.4)]</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">Cholelithiasis</span> <span class="Italics">[see Warnings and Precautions (5.5)]</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4254542" conceptname="Hypopituitarism">Pituitary hormone deficiency</span> <span class="Italics">[see Warnings and Precautions (5.6)]</span>
</li>
</ul>
<p><span class="Bold">Instruct the patients </span>on the proper use of SIGNIFOR, including instructions to:</p>
<ul class="Disc">
<li>Carefully review the Medication Guide.<br>
</li>
<li>Do not reuse unused portions of SIGNIFOR ampules and properly dispose of the ampules after use.<br>
</li>
<li>Avoid multiple injections at or near the same site within short periods of time. </li>
</ul>
<p>For instructions on the use of SIGNIFOR glass ampules, refer to the Medication Guide that follows.</p>
<p>** Trademark of Thomson Healthcare, Inc.</p>
<p>Manufactured by:<br>Novartis Pharma Stein AG<br>Stein, Switzerland</p>
<p>Distributed by:<br>Novartis Pharmaceuticals Corporation<br>East Hanover, NJ 07936</p>
<p>T2015-33</p>
<p>
		     
	</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="section-16"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Medication Guide</span></p>
<p><span class="Bold">SIGNIFOR</span><span class="Bold"><span class="Sup">®</span></span><span class="Bold"> [sig-na-for] </span></p>
<p><span class="Bold">(pasireotide)</span></p>
<p><span class="Bold">Injection</span></p>
<p>Read this Medication Guide before you start using SIGNIFOR and each time you get a refill. There may be new information. This information does not take the place of talking to your doctor about your medical condition or your treatment. </p>
<p><span class="Bold">What is the most important information I should know about SIGNIFOR?</span></p>
<p><span class="Bold">SIGNIFOR can cause serious side effects, including:</span></p>
<ul class="Disc"><li>
<span class="Bold">Low cortisol levels in your blood (hypocortisolism). </span>Tell your doctor right away if you have any signs and symptoms of hypocortisolism. Signs and symptoms of hypocortisolism may include:<ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span><br>
</li>
<li>loss of appetite<br>
</li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span><br>
</li>
<li>low level of sodium in your blood<br>
</li>
<li>low blood sugar</li>
</ul>
</li></ul>
<p>If you get hypocortisolism while taking SIGNIFOR, your doctor may change your dose or ask you to stop taking it.</p>
<br><ul class="Disc"><li>
<span class="Bold">High blood sugar (<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>). </span>Your doctor should check your blood sugar level before you start taking SIGNIFOR and while you take it. Signs and symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> may include:
						<ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">excessive thirst</span> <br>
</li>
<li>high urine output <br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span> with <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> <br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></li>
</ul>
</li></ul>
<p>If you get <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> while taking SIGNIFOR, your doctor may give you another medicine to take to lower your blood sugar. Your doctor may also change your dose of SIGNIFOR or ask you to stop taking it.</p>
<p><span class="Bold">What is SIGNIFOR?</span></p>
<p>SIGNIFOR is a prescription medicine used to treat Cushing’s disease in adults who cannot have surgery or have failed surgery. </p>
<p>It is not known if SIGNIFOR is safe and effective in children.</p>
<p><span class="Bold">What should I tell my doctor before using SIGNIFOR?</span></p>
<p><span class="Bold">Before you take SIGNIFOR, tell your doctor if you:</span></p>
<ul class="Disc">
<li>have or have had high blood sugar (<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>)<br>
</li>
<li>have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span><br>
</li>
<li>have or have had heart problems<br>
</li>
<li>have a history of low levels of potassium or magnesium in your blood<br>
</li>
<li>have or have had liver problems<br>
</li>
<li>have or have had <span class="product-label-link" type="condition" conceptid="196456" conceptname="Gallstone">gallstones</span><br>
</li>
<li>have any other medical conditions<br>
</li>
<li>are pregnant or plan to become pregnant. It is not known if SIGNIFOR will harm your unborn baby.<br>
</li>
<li>are breastfeeding or plan to breastfeed. It is not known if SIGNIFOR passes into your breast milk. You and your doctor should decide if you will take SIGNIFOR or breastfeed. You should not do both. </li>
</ul>
<p><span class="Bold">Tell your doctor about all the medicines you take</span>, including prescription and non-prescription medicines, vitamins, and herbal supplements.</p>
<p>Taking SIGNIFOR with certain other medicines can affect each other and cause side effects. Especially tell your doctor if you take: </p>
<ul class="Disc">
<li>medicines to control your heart beat (anti-arrhythmics) <br>
</li>
<li>medicines that can affect the electrical system of your heart (QT prolongation)<br>
</li>
<li>medicines to control your blood pressure (such as beta-blockers or calcium channel blockers) <br>
</li>
<li>medicines to control the electrolyte (such as potassium or magnesium) levels in your blood<br>
</li>
<li>cyclosporine (Gengraf<span class="Sup">®</span>, Neoral<span class="Sup">®</span>, Restasis<span class="Sup">®</span>, Sandimmune<span class="Sup">®</span>)<br>
</li>
<li>bromocriptine (Cycloset<span class="Sup">®</span>, Parlodel<span class="Sup">®</span>)</li>
</ul>
<p>Ask your doctor for a list of these medicines, if you are not sure.</p>
<p>Know the medicines you take. Keep a list of them to show to your doctor and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I use SIGNIFOR? </span></p>
<ul class="Disc">
<li>Read the <span class="Bold">“Instructions for Use?</span> at the end of this Medication Guide for information about the right way to use SIGNIFOR.<br>
</li>
<li>Use SIGNIFOR exactly as your doctor tells you to.<br>
</li>
<li>Your doctor may change your dose if needed.<br>
</li>
<li>Before you use SIGNIFOR for the first time, your doctor should do a blood test to check your blood sugar levels and your liver tests. <br>
</li>
<li>Before you use SIGNIFOR for the first time, your doctor should do a test to check your heart (electrocardiogram) and your gallbladder (ultrasound).<br>
</li>
<li>SIGNIFOR should be clear and colorless. Before you inject your dose, check to make sure that SIGNIFOR is clear and colorless, and does not have any clumps or particles in it. <br>
</li>
<li>SIGNIFOR is given as an injection into the fat just under your skin (subcutaneous injection).<br>
</li>
<li>
<span class="Bold">Do not</span> inject SIGNIFOR into skin that is red or irritated.<br>
</li>
<li>The recommended injection sites for SIGNIFOR are the top of your thigh or stomach area (abdomen). <br>
</li>
<li>Change (rotate) your injection site with each dose. <span class="Bold">Do not</span> inject SIGNIFOR into the exact same spot for each injection.<br>
</li>
<li>Your doctor should show you how to prepare and give your dose of SIGNIFOR before you use it for the first time.<br>
</li>
<li>You should not inject SIGNIFOR until your doctor has shown you how to use it the right way. <br>
</li>
<li>If you take too much SIGNIFOR, tell your doctor right away.</li>
</ul>
<p><span class="Bold">What are the possible side effects of SIGNIFOR? </span></p>
<p><span class="Bold">SIGNIFOR may cause serious side effects, including:</span></p>
<ul class="Disc">
<li>
<span class="Bold">See “What is the most important information I should know about SIGNIFOR??</span><br>
</li>
<li>
<span class="Bold">slow heart rate (<span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>). </span>SIGNIFOR can cause your heart to beat slower, which may cause you to feel weak, dizzy or even <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>. People who have, or have had, heart problems are at higher risk for <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>.<br>
</li>
<li>
<span class="Bold">problems with the electrical system of your heart (QT interval prolongation) which can put you at risk for abnormal heart beats, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span> spells that can be very serious. Call your doctor right away if you experience such spells.</span><br>
</li>
<li>
<span class="Bold">elevation of your liver tests. </span>Your doctor should do blood tests to monitor your liver tests while you use SIGNIFOR.<span class="Bold"> </span><br>
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="196456" conceptname="Gallstone">gallstones</span> (<span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">cholelithiasis</span>). </span>Your doctor should do an ultrasound to check for <span class="product-label-link" type="condition" conceptid="196456" conceptname="Gallstone">gallstones</span> before you start using SIGNIFOR and while you use it.</li>
</ul>
<p><span class="Bold">The most common side effects of SIGNIFOR include:</span> </p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span><br>
</li>
<li>high blood sugar <br>
</li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus<br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reactions</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span></li>
</ul>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away. </p>
<p>These are not all the possible side effects of SIGNIFOR. For more information, ask your doctor or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1–800–FDA–1088.</p>
<p><span class="Bold">How should I store SIGNIFOR? </span></p>
<ul class="Disc">
<li>Store SIGNIFOR at 68°F to 77°F (20°C to 25°C). <br>
</li>
<li>Keep SIGNIFOR out of the light.</li>
</ul>
<p><span class="Bold">Keep SIGNIFOR and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about the safe and effective use of SIGNIFOR.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use SIGNIFOR for a condition for which it was not prescribed. Do not give SIGNIFOR to other people, even if they have the same symptoms that you have. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about SIGNIFOR. If you would like more information, talk to your doctor. You can ask your pharmacist or doctor for information about SIGNIFOR that is written for health professionals.</p>
<p>For more information go to www.SIGNIFOR.com or call 1-877-503-3377.</p>
<p><span class="Bold">What are the ingredients in SIGNIFOR?</span></p>
<p><span class="Bold">Active ingredient:</span> Pasireotide</p>
<p><span class="Bold">Inactive ingredients: </span>Mannitol, tartaric acid, sodium hydroxide and water for injection. </p>
<p>T2012-224<br>December 2012</p>
</div>
<div class="Section" data-sectionCode="59845-8">
<a name="section-17"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Instructions for Use</span></p>
<p><span class="Bold">SIGNIFOR</span><span class="Bold"><span class="Sup">®</span></span><span class="Bold"> [sig-na-for] </span></p>
<p><span class="Bold">(pasireotide)</span></p>
<p><span class="Bold">Injection</span></p>
<p><span class="Bold">Supplies you will need to give your SIGNIFOR injection:</span></p>
<ul class="Disc">
<li>1 SIGNIFOR ampule (See Figure A)<br>
</li>
<li>1 sterile syringe (See Figure B)<br>
</li>
<li>1 long sterile needle (See Figure B) <ul class="Circle"><li>This needle is used to draw up your SIGNIFOR from the ampule. You should only use this needle if your doctor or nurse tells you to. </li></ul>
<br>
</li>
<li>1 short sterile needle (See Figure B)<br>
</li>
<li>Alcohol wipes<br>
</li>
<li>1 cotton ball or gauze<br>
</li>
<li>A sharps disposal container or other closeable, puncture resistant disposal container</li>
</ul>
<div class="Figure"><img alt="Figure A and Figure B" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=442f0d9d-5c7d-4b81-b329-d71be8cf2be2&amp;name=signifor-03.jpg"></div>
<p><span class="Bold">Getting started:</span></p>
<p><span class="Bold">Step 1: </span>Wash your hands well with soap and water and dry them.</p>
<p><span class="Bold">Step 2:</span> Take 1 SIGNIFOR ampule out of the box.</p>
<p><span class="Bold">Step 3:</span> Look at the SIGNIFOR ampule. Check that the ampule is not cracked or broken and that the liquid medicine in the ampule is clear and colorless. </p>
<p><span class="Bold">Do not</span> use SIGNIFOR if the ampule is cracked or broken or if the liquid looks cloudy or contains particles. Take the whole box back to the pharmacy and get a new one. </p>
<p><span class="Bold">Step 4: </span>Check the dose and expiration date printed on the ampule (See Figure C).</p>
<div class="Figure"><img alt="Figure C" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=442f0d9d-5c7d-4b81-b329-d71be8cf2be2&amp;name=signifor-04.jpg"></div>
<p>
		     
	<span class="Bold">Preparing your SIGNIFOR dose:</span></p>
<table>
<col width="360">
<col width="336">
<tbody class="Headless"><tr class="First Last">
<td class="Lrule Toprule">
<span class="Bold">Step 5: </span>Hold the SIGNIFOR ampule at the bottom with 1 hand. With your other hand, tap the top of the SIGNIFOR ampule with your finger to make sure there is no liquid in the top of the ampule when you open it (See Figure D).</td>
<td class="Rrule Toprule" align="center" valign="bottom">
<img alt="Figure D" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=442f0d9d-5c7d-4b81-b329-d71be8cf2be2&amp;name=signifor-05.jpg"><br>Figure D</td>
</tr></tbody>
</table>
<table>
<col width="360">
<col width="336">
<tbody class="Headless"><tr class="First Last">
<td class="Lrule Toprule">
<span class="Bold">Step 6: </span>Hold the ampule with 1 hand. With your other hand, hold the top of the ampule and<span class="Bold"> </span>pull it sideways until the top snaps off at the line marked on the ampule neck (See Figure E). <ul class="Disc"><li>Put the ampule upright on a clean and flat surface.</li></ul>
</td>
<td class="Rrule Toprule" align="center" valign="bottom">
<img alt="Figure E" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=442f0d9d-5c7d-4b81-b329-d71be8cf2be2&amp;name=signifor-06.jpg"><br>Figure E</td>
</tr></tbody>
</table>
<table>
<col width="360">
<col width="336">
<tbody class="Headless"><tr class="First Last">
<td class="Lrule Toprule">
<span class="Bold">Step 7:</span> Open the sterile needle package. Place the needle on the top of the syringe. Push down on the needle and twist it clockwise until it is tight (See Figure F). <ul class="Disc"><li>If you have been told to use 1 long and 1 short needle, you should use the long needle for this step. </li></ul>
</td>
<td class="Rrule Toprule" align="center" valign="bottom">
<br><img alt="Figure F" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=442f0d9d-5c7d-4b81-b329-d71be8cf2be2&amp;name=signifor-07.jpg"><br>Figure F</td>
</tr></tbody>
</table>
<table>
<col width="360">
<col width="336">
<tbody class="Headless"><tr class="First Last">
<td class="Lrule Toprule">
<span class="Bold">Step 8:</span> Pull the needle cover straight off the sterile needle (See Figure G).<br>
</td>
<td class="Rrule Toprule" align="center" valign="bottom">
<img alt="Figure G" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=442f0d9d-5c7d-4b81-b329-d71be8cf2be2&amp;name=signifor-08.jpg"><br>Figure G</td>
</tr></tbody>
</table>
<table>
<col width="360">
<col width="336">
<tbody class="Headless"><tr class="First Last">
<td class="Lrule Toprule">
<span class="Bold">Step 9: </span>Put the needle into the ampule making sure you do not touch the outside of the ampule and pull up on the plunger to draw up all of the SIGNIFOR liquid into the syringe (See Figure H).<ul class="Disc"><li>If you have been told to use 1 long and 1 short needle, you should now take the long needle off of the syringe and put on the short one.</li></ul>
</td>
<td class="Rrule Toprule" align="center" valign="bottom">
<br><br><img alt="Figure H" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=442f0d9d-5c7d-4b81-b329-d71be8cf2be2&amp;name=signifor-09.jpg"><br>Figure H</td>
</tr></tbody>
</table>
<table>
<col width="360">
<col width="336">
<tbody class="Headless"><tr class="First Last">
<td class="Lrule Toprule">
<span class="Bold">Step 10: </span>Hold the syringe upright in 1 hand between 2 fingers with your thumb at the bottom of the plunger. With your other hand, tap the syringe with your finger to get rid of air bubbles (See Figure I). </td>
<td class="Rrule Toprule" align="center" valign="bottom">
<br><img alt="Figure I" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=442f0d9d-5c7d-4b81-b329-d71be8cf2be2&amp;name=signifor-0A.jpg"><br>Figure I</td>
</tr></tbody>
</table>
<table>
<col width="360">
<col width="336">
<tbody class="Headless"><tr class="First Last">
<td class="Lrule Toprule">
<span class="Bold">Step 11: </span>Push up on the plunger until you see a drop of liquid on the tip of the needle (See Figure J). <ul class="Disc"><li>Do not let the needle touch anything. You are now ready to inject your dose of SIGNIFOR.</li></ul>
</td>
<td class="Rrule Toprule" align="center" valign="bottom">
<img alt="Figure J" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=442f0d9d-5c7d-4b81-b329-d71be8cf2be2&amp;name=signifor-0B.jpg"><br>Figure J</td>
</tr></tbody>
</table>
<p><span class="Bold">Injecting your SIGNIFOR dose:</span></p>
<table>
<col width="360">
<col width="336">
<tbody class="Headless"><tr class="First Last">
<td class="Lrule Toprule">
<span class="Bold">Step 12:</span> Choose your injection site and wipe the site with an alcohol wipe (See Figure K). Let the site dry.<br>
</td>
<td class="Rrule Toprule" align="center" valign="bottom">
<img alt="Figure K" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=442f0d9d-5c7d-4b81-b329-d71be8cf2be2&amp;name=signifor-0C.jpg"><br>Figure K</td>
</tr></tbody>
</table>
<table>
<col width="360">
<col width="336">
<tbody class="Headless"><tr class="First Last">
<td class="Lrule Toprule">
<span class="Bold">Step 13: </span>With 1 hand, gently pinch the skin at the injection site you have chosen and wiped with an alcohol wipe. With your other hand, pick up the syringe and hold it like a pencil. Insert the needle into the pinched skin at a 45 degree angle using a quick dart like motion (See Figure L).<ul class="Disc"><li>
<span class="Bold">Do not</span> let go of the skin. </li></ul>
</td>
<td class="Rrule Toprule" align="center" valign="bottom">
<br><img alt="Figure L" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=442f0d9d-5c7d-4b81-b329-d71be8cf2be2&amp;name=signifor-0D.jpg"><br>Figure L<br>
</td>
</tr></tbody>
</table>
<table>
<col width="360">
<col width="336">
<tbody class="Headless"><tr class="First Last">
<td class="Lrule Toprule">
<span class="Bold">Step 14:</span> Gently press the plunger all the way down, until the syringe is empty (See Figure M).</td>
<td class="Rrule Toprule" align="center" valign="bottom">
<br><br><img alt="Figure M" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=442f0d9d-5c7d-4b81-b329-d71be8cf2be2&amp;name=signifor-0E.jpg"><br>Figure M</td>
</tr></tbody>
</table>
<table>
<col width="360">
<col width="336">
<tbody class="Headless"><tr class="First Last">
<td class="Lrule Toprule">
<span class="Bold">Step 15: </span>When the syringe is empty,<span class="Bold"> </span>slowly let go of the skin and gently pull the needle out of the skin (See Figure N). </td>
<td class="Rrule Toprule" align="center" valign="bottom">
<br><img alt="Figure N" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=442f0d9d-5c7d-4b81-b329-d71be8cf2be2&amp;name=signifor-0F.jpg"><br>Figure N</td>
</tr></tbody>
</table>
<table>
<col width="360">
<col width="336">
<tbody class="Headless"><tr class="First Last">
<td class="Lrule Toprule">
<span class="Bold">Step 16: </span>Place a cotton ball or gauze over the injection site and press for about 5 seconds. <span class="Bold">Do not</span> massage the injection site. <ul class="Disc"><li>If there is <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, cover it with a bandage. </li></ul>
</td>
<td class="Rrule Toprule" align="center"></td>
</tr></tbody>
</table>
<p><span class="Bold">After injecting your SIGNIFOR dose: </span></p>
<ul class="Disc"><li>Put your used needles and syringes in a FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) loose needles and syringes in your household trash.<ul class="Circle">
<li>If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:<ul class="Square">
<li>made of a heavy-duty plastic,<br>
</li>
<li>can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,<br>
</li>
<li>upright and stable during use,<br>
</li>
<li>leak-resistant, and<br>
</li>
<li>properly labeled to warn of hazardous waste inside the container.</li>
</ul>
<br>
</li>
<li>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA’s website at: <span class="Underline">http://www.fda.gov/safesharpsdisposal</span> <br>
</li>
<li>Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.</li>
</ul>
</li></ul>
<p>This Medication Guide and Instructions for Use has been approved by the U.S. Food and Drug Administration.</p>
<p>Manufactured by:<br>Novartis Pharma Stein AG<br>Stein, Switzerland
		     
	</p>
<p>Distributed by:<br>Novartis Pharmaceuticals Corporation<br>East Hanover, NJ 07936</p>
<p>T2012-225<br>December 2012</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Principal display panel</span></p>
<p><span class="Bold">Package Label – </span><span class="Bold">0.3 mg/mL</span></p>
<p>Rx Only
		     
	
		     
	NDC 0078-0633-20<br>Signifor® <br>(pasireotide) Injection<br>0.3 mg/mL<br>For subcutaneous use only<br>60 ampules (10 packs of 6 ampules)</p>
<p><img alt="Package Label – 0.3 mg/mL
Rx Only		NDC 0078-0633-20
Signifor® 
(pasireotide) Injection
0.3 mg/mL
For subcutaneous use only
60 ampules (10 packs of 6 ampules)
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=442f0d9d-5c7d-4b81-b329-d71be8cf2be2&amp;name=signifor-10.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Principal display panel</span></p>
<p><span class="Bold">Package Label – </span><span class="Bold">0.6 mg/mL</span></p>
<p>Rx Only
		     
	
		     
	NDC 0078-0634-20<br>Signifor® <br>(pasireotide) Injection<br>0.6 mg/mL<br>For subcutaneous use only<br>60 ampules (10 packs of 6 ampules)</p>
<p><img alt="Package Label – 0.6 mg/mL
Rx Only		NDC 0078-0634-20
Signifor® 
(pasireotide) Injection
0.6 mg/mL
For subcutaneous use only
60 ampules (10 packs of 6 ampules)
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=442f0d9d-5c7d-4b81-b329-d71be8cf2be2&amp;name=signifor-11.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-20"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Principal display panel</span></p>
<p><span class="Bold">Package Label – </span><span class="Bold">0.9 mg/mL</span></p>
<p>Rx Only
		     
	
		     
	NDC 0078-0635-20<br>Signifor® <br>(pasireotide) Injection<br>0.9 mg/mL<br>For subcutaneous use only<br>60 ampules (10 packs of 6 ampules)</p>
<p><img alt="Package Label – 0.9 mg/mL
Rx Only		NDC 0078-0635-20
Signifor® 
(pasireotide) Injection
0.9 mg/mL
For subcutaneous use only
60 ampules (10 packs of 6 ampules)
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=442f0d9d-5c7d-4b81-b329-d71be8cf2be2&amp;name=signifor-12.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SIGNIFOR 		
					</strong><br><span class="contentTableReg">pasireotide injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0078-0633</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PASIREOTIDE</strong> (PASIREOTIDE) </td>
<td class="formItem">PASIREOTIDE</td>
<td class="formItem">0.3 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">49.50 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TARTARIC ACID</strong></td>
<td class="formItem">1.501 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem">4.2 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0078-0633-20</td>
<td class="formItem">60  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0078-0633-06</td>
<td class="formItem">6  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0078-0633-61</td>
<td class="formItem">1 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA200677</td>
<td class="formItem">12/14/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SIGNIFOR 		
					</strong><br><span class="contentTableReg">pasireotide injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0078-0634</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PASIREOTIDE</strong> (PASIREOTIDE) </td>
<td class="formItem">PASIREOTIDE</td>
<td class="formItem">0.6 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TARTARIC ACID</strong></td>
<td class="formItem">1.501 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem">4.2 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0078-0634-20</td>
<td class="formItem">60  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0078-0634-06</td>
<td class="formItem">6  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0078-0634-61</td>
<td class="formItem">1 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA200677</td>
<td class="formItem">12/14/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SIGNIFOR 		
					</strong><br><span class="contentTableReg">pasireotide injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0078-0635</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PASIREOTIDE</strong> (PASIREOTIDE) </td>
<td class="formItem">PASIREOTIDE</td>
<td class="formItem">0.9 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">49.50 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TARTARIC ACID</strong></td>
<td class="formItem">1.501 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem">4.2 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0078-0635-20</td>
<td class="formItem">60  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0078-0635-06</td>
<td class="formItem">6  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0078-0635-61</td>
<td class="formItem">1 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA200677</td>
<td class="formItem">12/14/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Novartis Pharmaceuticals Corporation
							(002147023)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 3/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>dd994d84-aaae-413e-9201-2ec5e7d1fcbd</div>
<div>Set id: 442f0d9d-5c7d-4b81-b329-d71be8cf2be2</div>
<div>Version: 2</div>
<div>Effective Time: 20150317</div>
</div>
</div> <div class="DistributorName">Novartis Pharmaceuticals Corporation</div></p>
</body></html>
